Novartis AG ADR (NVS)vsNexalin Technology Inc. (NXL)
NVS
Novartis AG ADR
$159.90
+3.74%
HEALTHCARE · Cap: $296.54B
NXL
Nexalin Technology Inc.
$0.36
+1.39%
HEALTHCARE · Cap: $7.78M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 20530417% more annual revenue ($56.58B vs $275,580). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
NXL
Avoid18
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.7%
Fair Value
$91.58
Current Price
$159.90
$68.32 premium
Intrinsic value data unavailable for NXL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -319.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : NXL
The strongest argument for NXL centers on Price/Book.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : NXL
The primary concerns for NXL are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a declining stock while NXL is a value play — different risk/reward profiles.
NXL carries more volatility with a beta of 3.83 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 18/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Nexalin Technology Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Nexalin Technology Inc. is an innovative leader in the medical technology sector, focused on revolutionizing the treatment landscape for neurological and psychiatric disorders through its proprietary transcranial electrical stimulation devices. The company’s non-invasive therapies address critical mental health challenges, including anxiety, depression, and substance addiction, underscoring its dedication to enhancing patient outcomes and advancing mental health solutions. With a solid foundation in research and a strategic emphasis on leveraging burgeoning demand for advanced healthcare innovations, Nexalin is poised for significant growth in the evolving digital health marketplace, making it an attractive prospect for institutional investors.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?